cryptoxanthins and Carcinoma--Hepatocellular

cryptoxanthins has been researched along with Carcinoma--Hepatocellular* in 3 studies

Trials

1 trial(s) available for cryptoxanthins and Carcinoma--Hepatocellular

ArticleYear
Phytochemicals in hepatocellular cancer prevention.
    Nutrition and cancer, 2009, Volume: 61, Issue:6

    Since the incidence of liver cancer is increasing in the world, it is valuable to develop an effective method for its prevention. Various phytochemicals have been shown to suppress liver carcinogenesis in experimental studies. Using these phytochemicals, a clinical trial was conducted. Combination of carotenoids and myo-inositol was found to prevent hepatocellular carcinoma development in patients with chronic viral hepatitis and cirrhosis.

    Topics: alpha-Tocopherol; Animals; Anticarcinogenic Agents; beta Carotene; Carcinoma, Hepatocellular; Carotenoids; Cryptoxanthins; Dietary Supplements; Hepatitis, Viral, Human; Humans; Inositol; Kaplan-Meier Estimate; Liver Cirrhosis; Liver Neoplasms; Lycopene; Male; Mice; Mice, Inbred C3H; Tumor Burden; Xanthophylls

2009

Other Studies

2 other study(ies) available for cryptoxanthins and Carcinoma--Hepatocellular

ArticleYear
Multicarotenoids at Physiological Levels Inhibit Metastasis in Human Hepatocarcinoma SK-Hep-1 Cells.
    Nutrition and cancer, 2015, Volume: 67, Issue:4

    Several studies have demonstrated that single carotenoid, including lycopene, β-carotene, and α-carotene, exhibits antimetastatic effects; however, little is known whether multicarotenoids have similar effects. Herein, we investigated the antimetastatic effect of multicarotenoids at physiological serum levels in Taiwanese (MCT at 1.4 μM) and American (MCA at 1.8 μM) populations using human hepatocarcinoma SK-Hep-1 cells in comparison with single carotenoid, such as lycopene (0.3 or 0.6 μM, respectively), α-carotene (0.1 μM), β-carotene (0.4 μM), lutein (0.4 or 0.5 μM, respectively), and β-cryptoxanthin (0.2 μM). Results reveal that MCA treatment exhibited an additive inhibition on invasion, migration and adhesion at 24 and 48 h of incubation, whereas MCT treatment possessed additive inhibition at 48 h of incubation. The antimetastatic action of MCT and MCA involved additive reduction on activities of matrix metalloproteinase (MMP)-2, -9, and protein expression of Rho and Rac 1 but additive promotion on protein expression of tissue inhibitor of MMP (TIMP)-1 and -2. All of these effects were stronger in MCA than in MCT at 24 and 48 h of incubation. These results demonstrate that multi-carotenoids effectively inhibit metastasis of human hepatocarcinoma SK-Hep-1 cells. More in vivo studies are needed to confirm these findings.

    Topics: beta Carotene; Carcinoma, Hepatocellular; Carotenoids; Cell Adhesion; Cell Line, Tumor; Cell Movement; Cryptoxanthins; Humans; Lutein; Lycopene; Matrix Metalloproteinase 2; Matrix Metalloproteinase 9; Neoplasm Metastasis; rac1 GTP-Binding Protein; rho-Associated Kinases; Tissue Inhibitor of Metalloproteinase-1; Tissue Inhibitor of Metalloproteinase-2

2015
Prediagnostic level of serum retinol in relation to reduced risk of hepatocellular carcinoma.
    Journal of the National Cancer Institute, 2006, Apr-05, Volume: 98, Issue:7

    Retinol and its derivatives (retinoids), which have antioxidant activity and promote cell differentiation, may protect against the development of hepatocellular carcinoma (HCC) by controlling hepatocellular differentiation and reducing inflammatory responses.. We examined prospectively the relationship between prediagnostic serum concentrations of retinol, alpha-carotene; beta-carotene; beta-cryptoxanthin; lutein; lycopene; zeaxanthin; alpha-, gamma-, and delta-tocopherols; and selenium and the risk of developing HCC among 213 patients with HCC and 1087 matched control subjects from a cohort of 18,244 men in Shanghai, China, who were monitored from 1986 through 2001. Odds ratios (ORs) and 95% confidence intervals (CIs) for men by quartile of serum concentrations of micronutrients were estimated by using logistic regression with adjustment for cigarette smoking status, alcohol intake, self-reported history of physician-diagnosed hepatitis or liver cirrhosis at recruitment, and seropositivity for hepatitis B surface antigen (HBsAg). All statistical tests were two-sided.. Men with high prediagnostic serum retinol levels had a lower risk of HCC than men in the lowest quartile (Q2 versus Q1, OR = 0.37, 95% CI = 0.22 to 0.61; Q3 versus Q1, OR = 0.30, 95% CI = 0.17 to 0.50; and Q4 versus Q1, OR = 0.13, 95% CI = 0.06 to 0.26; Ptrend < .001). A statistically significant interaction was observed between retinol and HBsAg seropositivity on HCC risk; HBsAg-positive men in the lowest tertile of retinol had a greater than 70-fold higher risk (OR = 72.7, 95% CI = 31.6 to 167.4) of HCC than HBsAg-negative men in the highest tertile of retinol (Pinteraction = .018). No independent effect of serum levels of alpha-carotene; beta-carotene; beta-cryptoxanthin; lutein; lycopene; zeaxanthin; alpha-, gamma-, and delta-tocopherols; or selenium on HCC risk were observed.. High prediagnostic serum level of retinol is associated with a decreased risk of HCC in this population.

    Topics: beta Carotene; Carcinoma, Hepatocellular; Carotenoids; Case-Control Studies; China; Cryptoxanthins; Humans; Incidence; Liver Neoplasms; Logistic Models; Lutein; Lycopene; Male; Micronutrients; Middle Aged; Odds Ratio; Prospective Studies; Risk Assessment; Risk Factors; Selenium; Tocopherols; Vitamin A; Xanthophylls; Zeaxanthins

2006